West Pharmaceutical Services Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.3B+15.0% YoYTTM through 30 Jun 2026
Net Income $564.9M+14.7% YoYTTM through 30 Jun 2026
Free Cash Flow $436.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 35.9% |
| EBITDA Margin | 25.9% |
| Operating Margin | 19.0% |
| Net Margin | 17.0% |
Returns
15.5%ROE
11.6%ROA
20.5%ROIC
Balance Sheet Health
Debt / Equity0.06x
Current Ratio3.02x
Net Debt-$588.5Mnet cash position
Cash & Equivalents$435.8M
Quality Metrics
Altman Z-Score17.72
Piotroski F-Score8 / 9
FCF Margin13.1%
Rule of 4014.6
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $3.1B
Diluted EPS$7.81TTMFY2025: $6.79
Dividend
$0.44Per share, FY20260.26%Yield-8.6%5-yr growth
Capital Allocation
R&D Spend$74.4M
Capex Intensity6.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Proprietary Products | $2.5B | View detailsExpected to continue driving growth in 2026, supported by robust demand for biologics and GLP-1 drug delivery solutions. | |
| Contract-Manufactured Products | $580.8M | View detailsDriven by growth in self-injection devices for obesity and diabetes therapies. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.